Oppenheimer analyst Jeff Jones lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $7.00 (from $8.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE